Women living close to federally designated Superfund sites are more likely to develop aggressive breast cancers — including the hard-to-treat triple-negative subtype — according to new studies from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in individual cancer cells. The technology, which can now use diverse types of pathology samples and quickly process large numbers of cells, has enabled the investigators to glean new insights into how cancers evolve toward greater aggressiveness and therapy resistance.

A new cancer treatment combines LED light and tiny tin flakes to neutralize cancer cells while shielding healthy cells and avoiding harmful side effects.

The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm successfully stimulated an effective anti-tumor immune response by reprogramming the death of malignant B cells. They demonstrated an effective triple-therapy approach for treating forms of blood cancer such as certain lymphomas and leukemias which affect B cells. The study was published on August 15 in the journal Science Advances.

Scientists have developed a highly sensitive single-cell tool that can help uncover links to complex diseases. Known as single-cell DNA-RNA-sequencing (SDR-seq), this tool created by scientists from EMBL's Genome Biology Unit can study both DNA and RNA simultaneously inside the same cell – a critical element in understanding how genetic variants impact gene expression in what’s called the non-coding region of the genome.

With SDR-seq, the scientists found that even small changes in DNA can change how genes are regulated in stem cells, and in a type of blood cancer called B-cell lymphoma.   

SDR-seq offers genome biologists scale, precision, and speed to help understand and eventually treat a broad range of diseases.

The advent of nanotechnology has ushered in a transformative era for oncology, offering unprecedented capabilities for targeted drug delivery and controlled release. This paradigm shift enhances therapeutic efficacy while mitigating the debilitating side effects associated with conventional cancer treatments. This essay explores the cutting-edge integration of various nano-delivery systems, highlighting the synergistic potential of synthetic nanoparticles, viral nanoparticles (VNPs), virus-like particles (VLPs), and magnetic hyperthermia to overcome the persistent drawbacks in malignant tumor therapy.

CiQUS researchers have developed a molecular strategy based on self-assembling peptide nanotubes to deliver drugs into the nucleus of chemotherapy-resistant cancer cells.

AI can be used to detect cervical cancer in women in resource-limited parts of the world. However, for this method to work, investments are needed in healthcare staff, reliable supply chains and trust in these communities. This has been shown in a new study from Uppsala University, Karolinska Institutet and the University of Helsinki, where researchers tested an AI-supported diagnostic method at rural hospitals in Kenya and Tanzania.